Abstract

69P Outcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Marie-France Savard ... Giovanni Zanotti
The Oncologist | VOL. 25
Marie-France Savard, et. al.Marie-France Savard ... Giovanni Zanotti
23 Jan 2020
Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Brian I Rini ... Robert A Figlin
Clinical genitourinary cancer | VOL. 16
Brian I Rini, et. al.Brian I Rini ... Robert A Figlin
04 May 2018
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
J.B.A.G Haanen ... R.J Motzer
ESMO open | VOL. 8
J.B.A.G Haanen, et. al.J.B.A.G Haanen ... R.J Motzer
25 Apr 2023
Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma.
...
International journal of urology : official journal of the Japanese Urological Association | VOL. 30
, et. al. ...
07 May 2023
View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title
Journal
Date
Author
Efficacy of TIL Therapy in Advanced Cutaneous Melanoma in the Current Immuno-oncology Era: Updated Systematic Review and Meta-analysis
S Martín-Lluesma ... G Coukos
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
S Martín-Lluesma, et. al.S Martín-Lluesma ... G Coukos
23 Jul 2024
Exploiting the tumor microenvironment and tumor mechanobiology for the treatment of cancer cachexia
Kostas A Papavassiliou ... Athanasios G Papavassiliou
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
Kostas A Papavassiliou, et. al.Kostas A Papavassiliou ... Athanasios G Papavassiliou
23 Jul 2024
Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story
N Colombo ... M Jalving
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
N Colombo, et. al.N Colombo ... M Jalving
22 Jul 2024
Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors
Rodrigo Sánchez-Bayona ... Mafalda Oliveira
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
Rodrigo Sánchez-Bayona, et. al.Rodrigo Sánchez-Bayona ... Mafalda Oliveira
22 Jul 2024
View more papers